Loading clinical trials...
Loading clinical trials...
A Phase II Study of Daratumumab and Ibrutinib for Relapsed / Refractory Chronic Lymphocytic Leukemia Treatment (DIRECT)
Conditions
Interventions
Daratumumab
Ibrutinib
Locations
1
United States
Mayo Clinic in Florida
Jacksonville, Florida, United States
Start Date
November 11, 2020
Primary Completion Date
May 1, 2023
Completion Date
February 13, 2025
Last Updated
December 30, 2025
NCT04169737
NCT06839053
NCT06859008
NCT05418088
NCT01815749
NCT02153580
Lead Sponsor
Mayo Clinic
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions